{"prompt": "['Trelagliptin-4002', 'Page 43 of 66', 'Version 2.0', 'July 5, 2017', 'monitoring of an abnormality are not considered medical practice. Also, repeated or additional', 'conduction of non-invasive tests for verification, evaluation, and monitoring of an abnormality are', 'not considered medical practice.', 'However, when abnormal laboratory values are the accompanying symptoms of a disease diagnosed', 'as an adverse event (e.g., increased creatinine due to renal dysfunction, etc.), the adverse event shall', 'be handled by its diagnosis name.', 'Pre-existing conditions (a disease or symptom that is present at the start of the screening period or', 'that is observed from the start of the screening period until before the start of study drug/or', 'comparative drug administration):', 'A disease or symptom that is present at the start of the screening period or that is observed from the', 'start of the screening period until before the start of study drug/ or comparative drug administration', 'are considered a comorbidity and not considered an adverse event. When a comorbidity is', 'aggravated, the aggravation shall be determined as an adverse event and the principal investigator or', 'the investigator shall record on the CRF that the adverse event is an aggravation of the comorbidity', '(e.g., \"aggravation of hypertension,\" etc.).', 'If a study subject has a pre-existing episodic condition (e.g., asthma, epilepsy), each episode shall be', 'recorded as an adverse event if the episodes become more frequent, serious, or severe in nature. If a', 'study subject has a chronic concurrent condition (e.g., cataracts, rheumatoid arthritis), worsening of', 'the condition shall be recorded as adverse event if the degree of the worsening exceeds that which', 'would be expected. The principal investigator or the investigator shall ensure that the adverse event', 'term to be reported represents the change in the condition from baseline (e.g. \"worsening of \").', 'Worsening of adverse events:', 'If a study subject experiences a worsening of the adverse event after a change of the study drug or', 'comparative drug, or secondary signs and symptoms are caused by the adverse event, the worsening', 'or the secondary signs and symptoms shall be recorded as a new adverse event on the CRF. The', 'principal investigator or the investigator shall use an adverse event term that explicitly means a', 'change of the condition (e.g., \"worsening of. \").', 'Change of severity of adverse events:', 'If the study subject experiences changes in the severity of an adverse event, the event shall be', 'recorded once, at its peak severity.', 'Previously planned surgery or treatment:', 'Preplanned surgeries or treatment that were scheduled before the start of study drug or comparative', 'drug administration shall not be considered adverse events. However, when the existing symptom is', 'aggravated to a degree requiring emergency surgery or treatment, the condition or the event shall be', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 44 of 66', 'Version 2.0', 'July 5,10', 'considered an adverse event. A complication that resulted from previously planned surgery shall be', 'reported as an adverse event.', 'Non-urgent surgery or treatment:', 'Non-urgent surgery or treatment that does not induce a change in the condition of a study subject', '(cosmetic surgery, etc.) shall not be considered an adverse event; However, it shall be recorded in', 'the source documents. Complications due to a non-urgent surgery shall be reported as an adverse', 'event.', 'The Insufficient clinical response (lack of efficacy):', 'Insufficient clinical response, efficacy, or pharmacological action shall not be recorded as an adverse', 'event. The principal investigator or the investigator shall make the distinction between worsening of', 'a pre-existing condition and lack of therapeutic efficacy.', 'Overdose of the study drug or comparative drug:', 'Overdose of any medication without manifested symptoms shall not be recorded as an adverse event,', 'but the overdose shall be recorded on the \"Overdose\" page of the CRF. Any manifested symptoms', 'shall also be recorded as adverse events on the \"Adverse events\" of the CRF.', '10.1.3 Serious adverse event', 'Of all the unfavorable medical events that develop with administration of a pharmaceutical product', '(including study drug/ or comparative drug) (irrespective of dose), a serious adverse event is an', 'event that:', '1. results in death,', '2. is life threatening*,', '3. requires inpatient hospitalization or prolongation of existing hospitalization,', '4.', 'results in persistent or significant disability/incapacity,', '5. leads to a congenital anomaly/birth defect, or', '6. other medically significant condition: a medically important event that causes a risk to a', 'study subject even if it is not immediately life-threatening and does not result in death or', 'hospitalization, or requires an action or treatment to prevent the results described in 1 to 5', 'above. In addition, points described in the Takeda Medically Significant Adverse Event List', '(Table 10 (a)) are included in this section.', '*', 'The term \"life threatening\" refers to an event in which the study subject was at risk of death at the', 'time of the event; it does not refer to an event that hypothetically might have caused death if it was', 'more severe.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 45 of 66', 'Version 2.0', 'July 5,10', 'Table 10.a', 'Takeda Medically Significant AE List', 'Acute respiratory failure/acute respiratory', 'Hepatic necrosis', 'distress syndrome (ARDS)', 'Acute hepatic failure', 'Torsades de bointes/ventricular', 'Anaphylactic shock', 'fibrillation/ventricular tachycardia', 'Acute renal failure', 'Malignant hypertension', 'Pulmonary hypertension', 'Convulsive seizure (including convulsion', 'Pulmonary fibrosis (including interstitial', 'and epilepsy)', 'pneumonia)', 'Agranulocytosis', 'Neuroleptic malignant syndrome/ malignant', 'Aplastic anemia', 'hyperpyrexia', 'Toxic epidermal necrolysis/', 'Spontaneous abortion/ stillbirth and fetal death', 'Oculomucocutaneous syndrome', 'Confirmed or suspected transmission of infection', '(Stevens-Johnson syndrome)', 'by a medicinal product', 'Confirmed or suspected endotoxin shock', '10.1.4 Adverse events of special interest (specific adverse events)', 'An AE of Special Interest (AESI) (serious or non-serious) is one of scientific and medical concern', 'specific to the study drug or comparative drug, for which ongoing monitoring and rapid', 'communication by the principal investigator or investigator to Takeda may be appropriate. Such', 'events may require further investigation in order to establish assessment, and instructions provided', 'to investigators on how and when they should be reported to the sponsor are described in Section', '10.2.1.3.', '10.1.5 Severity of adverse events', 'The severity of adverse events shall be classified and defined as shown below.', 'Mild', 'The event is transient and easily tolerated by the subject.', 'Moderate', \"The event interrupts the subject's usual activities.\", 'Severe', \"The event causes considerable interference with the subject's usual activities.\", '10.1.6 Causality of adverse events', 'The causal relationship of each adverse event to the study drug or comparative drug shall be', 'classified and defined as shown below.', 'An adverse event that follows a temporal sequence (including clinical course after', 'Related', 'discontinuation), or an adverse event in which there is at least a reasonable', 'CONFIDENTIAL']", "completion": ""}